Entrant Adverse Events: FDA MAUDE Data

ABBOTT (ST. JUDE MEDICAL) · CRT-Defibrillator (CRT-D) · First cleared May 2024

Total Reports

338

Reports (30d)

16

Active Signals

1

Open Recalls

2

Monthly Report Volume
Event Type Breakdown

Most commonly reported problems

1

Technical Support Recommended Reprogramming

observed device, reprogramming, support contacted, episodes post, adverse consequences

6

reports

2

High Pacing Impedance During Implant Procedure

lead, impedance, event patient, resolve event, implant procedure

4

reports

3

Remote Follow-Up Revealed T-Wave Over-Sensing

device technical, exhibited post, remote follow, support contacted, oversensing pptwos

3

reports

4

Post-Paced T-Wave Oversensing Observed

wave oversensing, paced wave, transmission, oversensing observed, post paced

2

reports

5

Post-Paced T-Wave Over-Sensing with No Further Info

implantable cardioverter, defibrillator exhibited, cardioverter, cardioverter defibrillator, post paced

2

reports

6

Remote Transmission Revealed T-Wave Over-Sensing

transmission revealed, remotely merlin, net review, merlin net, presented remotely

2

reports

Problem groupings are generated by Claripulse from report narrative text. They summarize what reporters wrote, not adjudicated root cause.

Active safety signals

Disproportionate reportinghigh

FDA recalls for this device

Class II

Aug 16, 2023 · Open, Classified

Due to Bluetooth malfunction on a subset of Implantable Cardioverter Defibrillator (ICD) and Cardia Resynchronization Therapy Defibrillator *CRT-D) devices that were manufactured prior to April 2022 as a result of crystal component issue within the Bluetooth Low Energy (BLE) circuit. This results in the device entering an inductive telemetry only mode with loss of Bluetooth communication. In some instances, thought BLE communication is unavailable, the circuit may remain in a state which draws excessive power affecting battery longevity.

Class II

Mar 10, 2022 · Open, Classified

Due to a programmer software anomaly under very specific circumstance when executing a pacing capture Decrement Test in-clinic on implantable cardioverter and cardiac resynchronization therapy defibrillator devices, the programmer may continue to execute the Decrement Test instead of terminating the test and restoring the permanent programmed pacing parameters.

Want automated safety signal detection?

Claripulse monitors these devices weekly and detects anomalies using 6 statistical methods — spike, trend, changepoint, peer-outlier, and more. 1 active signal detected right now.

Get Early Access
Disclaimer: This system analyzes publicly available FDA MAUDE data. It does NOT provide medical advice. MAUDE data is de-identified. Do not attempt re-identification. Report counts may differ from the FDA's MAUDE search due to processing cadence and deduplication. Data is updated weekly.